Verrica Pharmaceuticals (VRCA) Net Income towards Common Stockholders (2021 - 2025)
Historic Net Income towards Common Stockholders for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to -$308000.0.
- Verrica Pharmaceuticals' Net Income towards Common Stockholders rose 9865.26% to -$308000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.7 million, marking a year-over-year increase of 7217.63%. This contributed to the annual value of -$73.9 million for FY2024, which is 1035.07% down from last year.
- Per Verrica Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at -$308000.0 for Q3 2025, which was up 9865.26% from $204000.0 recorded in Q2 2025.
- Over the past 5 years, Verrica Pharmaceuticals' Net Income towards Common Stockholders peaked at $204000.0 during Q2 2025, and registered a low of -$24.8 million during Q3 2023.
- Over the past 5 years, Verrica Pharmaceuticals' median Net Income towards Common Stockholders value was -$10.2 million (recorded in 2022), while the average stood at -$11.1 million.
- In the last 5 years, Verrica Pharmaceuticals' Net Income towards Common Stockholders crashed by 2998192.77% in 2023 and then soared by 10118.7% in 2025.
- Verrica Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$9.5 million in 2021, then skyrocketed by 37.89% to -$5.9 million in 2022, then crashed by 316.02% to -$24.6 million in 2023, then soared by 45.01% to -$13.6 million in 2024, then surged by 97.73% to -$308000.0 in 2025.
- Its Net Income towards Common Stockholders stands at -$308000.0 for Q3 2025, versus $204000.0 for Q2 2025 and -$10.0 million for Q1 2025.